Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,493 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patch 2 Clear all
Completed Phase 2 Interventional Results available

Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk

NCT00861146
View directory record Official record
Conditions
Tobacco Use Cessation, Alcohol-related Disorders
Interventions
behavioral counseling plus contingency management
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Newington, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 22, 2026, 10:26 AM EDT
Recruiting Phase 2 Interventional

Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

NCT05726383
View directory record Official record
Conditions
Osteogenic Sarcoma Recurrent
Interventions
Iscador*P
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
8 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

NCT02542631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 22, 2026, 10:26 AM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Active, not recruiting Not applicable Interventional Results available

MRI Guided SBRT for Localized Prostate Cancer

NCT03778112
View directory record Official record
Conditions
Prostate Cancer
Interventions
SBRT to whole prostate, IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions
Radiation
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Results available

Combination Nicotine Patch / Lorcaserin for Smoking Cessation

NCT02906644
View directory record Official record
Conditions
Nicotine Dependence
Interventions
lorcaserin, nicotine patch, placebo lorcaserin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 22, 2026, 10:26 AM EDT
Withdrawn Phase 1 Interventional

Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia

NCT05505539
View directory record Official record
Conditions
Oral Leukoplakia
Interventions
5-fluorouracil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.

NCT00661765
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline tartrate, varenicline free base
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2009 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Results available

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NCT02354534
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 22, 2026, 10:26 AM EDT
Recruiting Early Phase 1 Interventional

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

NCT05838599
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Imiquimod, Radiation Therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

NCT01582932
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene 0.005% Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects

NCT04319926
View directory record Official record
Conditions
Healthy
Interventions
lidocaine topical system 1.8%, lidocaine patch 5%
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

DuraSeal Sealant Post Market Study

NCT00704340
View directory record Official record
Conditions
Elective Cranial Procedures With Dural Incision
Interventions
DuraSeal Dural Sealant System, Standard of Care
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery

NCT01592708
View directory record Official record
Conditions
Post-operative Nausea, Post-operative Vomiting, Nausea Persistent
Interventions
Antiemetic anesthesia protocol
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Body Temperature in Persons With Tetraplegia When Exposed to Cold

NCT01822535
View directory record Official record
Conditions
Tetraplegia, Hypothermia, Mild Cognitive Impairment
Interventions
Midodrine hydrochloride
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 68 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 22, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

NCT03363763
View directory record Official record
Conditions
Angiofibroma of Face, Tuberous Sclerosis
Interventions
Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment
Drug
Lead sponsor
Aucta Pharmaceuticals, Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)

NCT00365209
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Tobacco Use Disorder
Interventions
laboratory biomarker analysis, pharmacological study, curcumin
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels

NCT03097484
View directory record Official record
Conditions
Neonatal Abstinence Syndrome, Aromatherapy
Interventions
lavender and chamomile essential oils
Drug
Lead sponsor
John M. Daniel
Other
Eligibility
Up to 2 Weeks
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 22, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

NCT01464593
View directory record Official record
Conditions
Colon Cancer Liver Metastasis
Interventions
Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox
Drug · Other
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • The Bronx, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 22, 2026, 10:26 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and/or Vomiting (PONV)

NCT00775749
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
transdermal nicotine patch, placebo patch
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

US Cycle Control and Blood Pressure Study

NCT00920985
View directory record Official record
Conditions
Contraception
Interventions
Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
28
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants

NCT04532164
View directory record Official record
Conditions
Dermatitis, Photoallergic
Interventions
Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Determinants of Smoking Cessation Among Latinos

NCT01008748
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Replacement Therapy (NRT), Questionnaire, Counseling, Self-Help Materials
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 22, 2026, 10:26 AM EDT
Completed Phase 4 Interventional Results available

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

NCT02420015
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Nicotine replacement therapy, Bupropion, cognitive-behavioral smoking cessation counseling, Mobile Contingency Management, Stay Quit Coach, SMS text messaging
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 22, 2026, 10:26 AM EDT